# High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2

> **NCT00080977** · PHASE2 · UNKNOWN · sponsor: **Blumenthal Cancer Center at Carolinas Medical Center**

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** aldesleukin

## Key facts

- **NCT ID:** NCT00080977
- **Lead sponsor:** Blumenthal Cancer Center at Carolinas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1998-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080977, "High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00080977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*